Keeping Track: Busy August Ends With Approval For Doravirine, CRLs For Dasotraline And Waylivra
Executive Summary
The latest drug development news and highlights from our US FDA Performance Tracker.
You may also be interested in...
New CEO Brett Monia Takes The Lead As Ionis Prioritizes Non-Partnered Programs
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
Janssen's Imbruvica Leads CLL Market Expansion In Europe
Imbruvica is keeping ahead of potential competitors in Europe by expanding its use in patients with chronic lymphocytic leukemia and Waldenström’s macroglobulinemia.